Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
11:01am, Friday, 02'nd Dec 2022 Benzinga
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.
Th
Is Amgen Stock a Buy for Income Investors?
06:40am, Friday, 02'nd Dec 2022
Amgen's dividend yield is materially higher than the S&P 500 index's yield.
The S&P 500 is on the cusp of breaking through a level that might spell the end of the bear market
07:48pm, Thursday, 01'st Dec 2022 MarketWatch
Still, new 52-week highs made by individual stocks is low, putting on hold a 'buy' signal.
Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly
09:30am, Thursday, 01'st Dec 2022
Amgen stock could get a fresh boost Thursday after the company unveiled promising results for its obesity treatment. The post Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Nov
Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics' Buyout
06:52pm, Wednesday, 30'th Nov 2022 Benzinga
Horizon Therapeutics Plc (NASDAQ: HZNP) confirmed it's engaged in preliminary talks with Amgen Inc (NASDAQ: AMGN), Janssen Global Service, and Sanofi SA SNY on potential takeover offers for th
Horizon (HZNP) Up on Initial Talks of Buyout by Pharma Giants
04:49pm, Wednesday, 30'th Nov 2022 Zacks Investment Research
Horizon (HZNP) holds preliminary discussions with Amgen, Sanofi and Janssen, a subsidiary of J&J, seeking an offer for its acquisition by any one of the pharma giants. Shares rise.
Why Horizon Therapeutics Stock Is Skyrocketing Today
04:15pm, Wednesday, 30'th Nov 2022 The Motley Fool
Three big drugmakers could be interested in acquiring Horizon.
Banks are short more than $1 trillion in capital, says this analyst, who fears the shortfall will only get worse
01:37pm, Wednesday, 30'th Nov 2022 MarketWatch
If bank assets are marked to market, the U.S. sector is insolvent, according to an independent analyst.
Horizon Therapeutics in preliminary sale talks with Amgen, Sanofi, J&J
10:37am, Wednesday, 30'th Nov 2022
CNBC's Jim Cramer and the 'Squawk on the Street' team discuss a new report that Horizon Therapeutics is in preliminary talks with major pharmaceutical companies over a potential takeover.
Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi
05:38pm, Tuesday, 29'th Nov 2022
Horizon said Tuesday it's considering potential offers from three Big Pharma stalwarts, sending HZNP stock soaring more than 30% after hours. The post Horizon Therapeutics Rockets As It Considers Pote
Amgen Inc. (AMGN) Presents at Evercore ISI HealthCONx Conference (Transcript)
05:26pm, Tuesday, 29'th Nov 2022
Start Time: 11:20 January 1, 0000 11:58 AM ET Amgen Inc. (NASDAQ:AMGN ) Evercore ISI HealthCONx Conference November 29, 2022, 11:20 AM ET Company Participants David Reese - EVP, Research and Developme
The Most-Sold Guru Stocks of the 3rd Quarter
06:11pm, Monday, 28'th Nov 2022
The third quarter of 2022 was another discouraging period for investors. Inflation kept going strong, the Federal Reserve continued raising interest rates and even the housing market began showing sig
Best Dividend Stocks To Buy Now? 2 To Watch Before December 2022
03:12pm, Monday, 28'th Nov 2022
2 top health care dividend stocks to check out ahead of December 2022.
Beat the Market the Zacks Way: Tenaris, Lululemon, AutoZone in Focus
11:58am, Monday, 28'th Nov 2022 Zacks Investment Research
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
4 Pharmaceutical Companies Among 19 To Announce Annual Dividend Increases In December
05:00am, Monday, 28'th Nov 2022
Among the 19 companies that are expected to announce annual dividend increases in December are drugmakers Eli Lilly, Pfizer, Bristol Myers Squibb, and Amgen. Investors are also waiting for Merck's inc
